News and Announcements
Proteomics March Update: PromarkerD Progress, Indian Biotech Market Expansion & Solid Quarter Results
- Published April 26, 2016 11:48AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th April 2016, ASX Announcement
Life sciences company Proteomics International Laboratories Ltd (ASX:PIQ) (the Company, PILL) is pleased to provide the following update on its business activities for the three month period to 31 March 2016.
Highlights
- PromarkerD progress: 500 patient follow-up validation study underway to further validate PromarkerD’s initial ground-breaking results.
- IVD test kit for PromarkerD: Assessing development program to produce a clinical pathology In Vitro Diagnostic (IVD) test kit for PromarkerD.
- Therapeutic Drug Discovery Program: to discover new analgesic and antibiotics drug compounds.
- Analytical Services operations: Solid quarter-on-quarter results.
- Business Development: Company expands operations in massive Indian biotech market.
The March quarter delivered another period of sound performance for PILL. During the quarter, it embarked on a number of programs utilising its proprietary, disruptive technology platform. This included a development program, to produce a standard clinical pathology In Vitro Diagnostic (IVD) test kit for PromarkerD.
To view the full article, please click on the button below.